GI
GILD
HealthcareGilead Sciences, Inc.
Drug Manufacturers - General
Total Trades
16
Unique Traders
7
Purchases / Sales
12/4
News Articles
5
Trading History
| Date | Politician | Asset | Action | Amount | Trade Price | 30D Price | 1M Return | Alpha | 1M Prediction |
|---|---|---|---|---|---|---|---|---|---|
May 15, 2026 |  Rohit KhannaD | Stock | Buy | $15,001 - $50,000 | $129.58 | $125.59 | -3.1% | -3.4% | |
May 6, 2026 |  Jared MoskowitzD | Stock | Buy | $1,001 - $15,000 | $135.41 | $128.32 | -5.2% | -5.7% | |
May 6, 2026 | Jared MoskowitzD | Stock | Buy | $1,001 - $15,000 | $135.41 | $128.32 | -5.2% | -5.7% | |
Apr 13, 2026 | Rohit KhannaD | Stock | Sell | $15,001 - $50,000 | $139.03 | $133.05 | -4.3% | -12.5% | |
Jan 29, 2026 | Rohit KhannaD | Stock | Buy | $15,001 - $50,000 | $138.76 | $148.11 | +6.7% | +7.9% | |
Jan 27, 2026 |  Josh GottheimerD | Stock | Buy | $1,001 - $15,000 | $140.17 | $142.96 | +2.0% | +2.9% | |
Sep 23, 2025 |  Valerie HoyleD | Stock | Sell | $1,001 - $15,000 | $113.01 | $119.27 | +5.5% | +4.3% | |
Jun 6, 2025 |  Marjorie Taylor Greene | Stock | Buy | $1,001 - $15,000 | $109.55 | $109.63 | +0.1% | -4.6% | |
May 14, 2025 | Josh GottheimerD | Stock | Sell | $1,001 - $15,000 | $95.83 | $107.89 | +12.6% | +11.0% | |
May 12, 2025 |  Jefferson ShreveR | Stock | Sell | $15,001 - $50,000 | $101.13 | $106.47 | +5.3% | +2.1% | |
May 5, 2025 | Marjorie Taylor Greene | Stock | Buy | $1,001 - $15,000 | $100.15 | $106.20 | +6.0% | +0.3% | |
Mar 31, 2025 | Jefferson ShreveR | Stock | Buy | $15,001 - $50,000 | $109.15 | $103.78 | -4.9% | -4.1% | |
Mar 10, 2025 |  Carol Devine MillerR | Stock | Buy | $1,001 - $15,000 | $114.02 | $103.11 | -9.6% | -7.7% | |
Mar 7, 2025 | Josh GottheimerD | Stock | Buy | $1,001 - $15,000 | $114.22 | $105.07 | -8.0% | +4.0% | |
Oct 29, 2024 | Valerie HoyleD | Stock | Buy | $1,001 - $15,000 | $84.97 | $89.15 | +4.9% | +2.0% |
Recent News
Sector Update: Healthcare Stocks Gain Late Afternoon
Yahoo-Invalid Date
GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment
Yahoo-Invalid Date
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
Yahoo-Invalid Date
FDA Approves First Treatment For Chronic Hepatitis Delta Virus (HDV) Infection
Benzinga-Invalid Date
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
Yahoo-Invalid Date